

1 **Clinical Validation of Automated and Rapid mariPOC SARS-CoV-2 Antigen**

2 **Test**

3 Juha M. Koskinen,^{a,b*} Petri Antikainen,^a Kristina Hotakainen,^{c,d} Anu Haveri,^e Niina Ikonen,^e
4 Carita Savolainen-Kopra,^e Janne O. Koskinen^a

5 ^aArcDia International Ltd, Turku, Finland

6 ^bFaculty of Medicine, University of Turku, Turku, Finland

7 ^cMehiläinen Oy, Helsinki, Finland

8 ^dDepartment of Clinical Chemistry and Haematology, University of Helsinki, Helsinki, Finland

9 ^eFinnish Institute for Health and Welfare, Helsinki, Finland

10 *Address correspondence to Juha Koskinen, juha.koskinen@arcDia.com

11 JMK and PA contributed equally to the manuscript.

12 **ABSTRACT** Novel SARS coronavirus causing COVID-19 was recognized in late 2019.
13 Diagnostics was quickly ramped up worldwide based on the detection of viral RNA. Based on
14 the scientific knowledge for pre-existing coronaviruses, it was expected that the RNA of this
15 novel coronavirus will be detected at significant rates from symptomatic and asymptomatic
16 individuals due to existence of non-infectious RNA. To increase the efficacy of diagnostics,
17 surveillance, screening and pandemic control, rapid methods, such as antigen tests, are needed
18 for decentralized testing and to assess infectiousness. The objectives were to verify analytical
19 sensitivity and specificity, and assess the clinical sensitivity, specificity and usability of a novel

20 automated mariPOC SARS-CoV-2 test based on sophisticated optical laser technology detecting
21 viral structure proteins. Analytical performance was verified using bacterial and viral
22 preparations. Clinical performance of the test was evaluated against qRT-PCR in a retrospective
23 study with nasopharyngeal swab specimens (N=211) collected from symptomatic patients
24 suspected of acute SARS-CoV-2 infections. Sensitivity and specificity of the mariPOC test were
25 92.3% (12/13) and 100.0% (198/198), respectively. The test's limit of detection was 22 PFU/test
26 and it had no cross-reactions with the tested respiratory microbes. Our study shows that the
27 mariPOC can detect infectious individuals already in 20 minutes while clinical sensitivity close
28 to qRT-PCR is achieved in two hours or less. The test targets conserved epitopes of SARS-CoV-
29 2 nucleoprotein, making it robust against strain variations. The new test is a promising and
30 versatile tool for syndromic testing of symptomatic cases and for high capacity infection control
31 screening.

32 **KEYWORDS** COVID-19, SARS-CoV-2, antigen detection, mariPOC, PCR, infectious,
33 screening, infection control, pandemic

34 Emerging pandemic coronavirus (CoV) was recognized in Wuhan, China, in late 2019. The
35 virus, isolated from patients mentioned to be pneumonic, was quickly sequenced to share 79.6%
36 full length genome similarity with the Severe Acute Respiratory Syndrome virus (SARS-CoV-1)
37 and 91.2% similarity between its nucleocapsid (N) proteins (1). The novel SARS-CoV-2,
38 causing COVID-19, was identified to be circulating in horseshoe bats for decades similarly to
39 SARS-CoV-1 (2). Diagnostic nucleic acid amplification tests (NAAT), mostly quantitative real-
40 time polymerase chain reaction (qRT-PCR), were quickly developed worldwide, based on
41 protocol provided for World Health Organization (3). Diagnostic qRT-PCR capacities were
42 ramped up quickly in central laboratories because such tests are fast to develop for new targets.

43 Most often, the new qRT-PCR tests were adopted for clinical diagnostics with minimal
44 verification and validation against other diagnostic test methods, such as viral culture and
45 serology.

46 For the seasonal coronaviruses, the interpretation of gene positivity in clinical specimens has
47 been challenging since the viral RNA is detected at similar rates and qRT-PCR cycle threshold
48 (Ct) values from symptomatic and asymptomatic individuals. The viral RNA is also co-detected
49 with genomes of other respiratory viruses (4-7). This is also the case for the SARS-CoV-2 (8, 9).
50 Moreover, recent scientific evidence indicates that qRT-PCR positivity has poor correlation for
51 assessment of SARS-CoV-2 infectiousness (10-16). Whereas, Pekosz et al. (2020) showed that
52 the detection of N-protein by an antigen test correlates with SARS-CoV-2 viral culture more
53 accurately than qRT-PCR (13). Already half a decade ago Inagaki et al. (2016) unequivocally
54 concluded for influenza that, “PCR...is not an appropriate method for indicating infectivity” and
55 “the antigen-detection test estimated the infectious period with comparable if not better accuracy
56 with culture” (17). In the case of COVID-19 diagnostics, the fact that viral RNA persistence can
57 be detected without viable virus for months, has been a known clinical challenge, as diagnostics
58 relied in the beginning of the pandemic solely on NAAT detection (18), the efficacy of which is
59 in ruling out positivity.

60 The expression of N-protein, which is the key pathogenicity factor of coronaviruses (19), is
61 essential for the coronavirus replication and transcription of the viral RNA (20, 21). Without the
62 accumulation of the N-protein, the coronaviral mRNA is degraded by the nonsense-mediated
63 decay (NMD) pathway of eukaryotic cells (19). Alexandersen et al. (2020) concluded that the
64 detection of RNA is not an indicator of actively replicating SARS-CoV-2. Their data suggests

65 that virion and subgenomic RNAs are stable in cellular double-membrane vesicles and, therefore,
66 can be detected long after the acute infection (22).

67 Shortly after viral exposure, viral concentration is low and qRT-PCR Ct values are high. When
68 the virus starts replication, it happens fast. In a cell model, extensive coronavirus RNA
69 transcription has occurred in 6 to 8 hours after the infection (23). In addition, NAATs being
70 prone for reporting clinically insignificant findings (analytically the detection may be correct,
71 there is viral RNA in the sample) they are prone to contaminations. A study of SARS-CoV-2
72 primer-probe sets from four major European suppliers found a significant level of contamination
73 from the reagents. False positives as low as qRT-PCR Ct 17 were obtained (24). Low levels of
74 SARS-CoV-2 RNA contamination has also been found from surfaces and air in rooms where
75 mildly ill individuals were isolated without notable viable virus (25, 26). It has also been shown
76 that environmental contamination may yield in positive test results in PCR among individuals
77 sampled in the same area where intranasal influenza vaccine dosing was done (27). These data
78 suggests that individuals having presence near symptomatic patients can be contaminated by
79 RNA without being infected with viable virus. Thus, methods detecting the viral RNA by
80 amplification are prone for clinically insignificant positive results, especially when significant
81 part of the population has been infected recently. The fact that a positive NAAT result is not a
82 reliable biomarker of active infection or COVID-19, is a true challenge for clinicians and
83 decision making for quarantine. It is not only that a missed necessary quarantine has health and
84 epidemic costs but also that a falsely imposed quarantine has social and financial consequences
85 (28).

86 The different performance requirements of diagnostic, surveillance and screening testing have
87 been recently discussed by Mina and Andersen (2020). There is a need for both super sensitive

88 PCR based tests and rapid and appropriately sensitive antigen tests to fight the COVID-19
89 pandemic (29). The use of the two methodologies should supplement one another in clinical
90 practice and pandemic fight.

91 In the present study, we analytically and clinically validated the performance of a novel
92 mariPOC SARS-CoV-2 test (ArcDia International Ltd, Finland), intended for rapid and
93 automated detection of viral acute phase proteins when there is a clinical suspicion of acute
94 COVID-19. Monoclonal antibodies of the test are designed to target a conserved epitope in the
95 N-protein, which is the most abundant protein in coronaviruses. We have previously shown that
96 the presence of coronavirus OC43 N-protein in the nasopharynx correlates with the respiratory
97 tract infection symptoms (30). It has been shown that clinical presentations of seasonal
98 coronavirus OC43 infections can be similar to those of coronaviruses that are considered as
99 severe viruses (SARS and MERS) (31).

100 The mariPOC is an automated platform for the rapid multianalyte testing of acute infectious
101 diseases. It is based on a separation-free two-photon excitation assay technique (32, 33).

102 Subsequently to nasopharyngeal sampling, the mariPOC test's operational steps are: combining
103 the swab with the sample buffer from a bottle-top dispenser, vortexing the sample tube to release
104 the sample from the swab (Figure 1), followed by automated analysis and objective fluorescent
105 result read out. The analysis is performed by an automated analyzer with sophisticated
106 autoverification functions, and the result can be transferred automatically to the laboratory
107 information system or as anonymized epidemiological data (34) into mariCloud™ service. The
108 hands-on time is one minute per sample, and the analyzer works in continuous-feed and walk-
109 away mode. The mariPOC SARS-CoV-2 test is available as a single pathogen test and as part of
110 syndromic multianalyte tests covering, among others, influenza viruses. The throughput of one

111 mariPOC analyzer can be up to 300 single analyte tests or 100 multianalyte tests in 24 hours. The
112 results are reported in two phases, highly infectious cases in twenty minutes and low positive and
113 negative cases in two hours or less, depending on the test configuration.

114 **MATERIALS AND METHODS**

115 **Analytical sensitivity.** Nasopharyngeal swab specimens from asymptomatic individuals were
116 suspended into mariPOC RTI sample buffer into volume corresponding to 1.3 mL per swab. This
117 pooled clinical sample matrix was spiked with 75 μ L of UV-inactivated SARS-CoV-2 culture
118 supernatant (2×10^6 PFU/mL, Ct 17, University of Helsinki, Finland) per swab in different
119 concentrations (plaque-forming unit). The samples were analyzed with the mariPOC SARS-
120 CoV- 2 test following the manufacturer's instructions. Preparation of the virus is described in the
121 referenced study (35). Limit of Detection (LoD) was determined as the lowest concentration
122 giving at least 19 positives out of 20 replicates ($\geq 95\%$ positivity).

123 **Cross-reactivity.** Analytical specificity of the mariPOC SARS-CoV-2 test was studied by
124 challenging the test against relevant microbes commonly found in the nasal cavity (supplemental
125 material). Briefly, the microbe stocks were suspended in high concentration in the mariPOC RTI
126 sample buffer and analyzed with the mariPOC SARS-CoV-2 test.

127 **Verification.** For preliminary validation of the mariPOC SARS-CoV-2 test forty five positive
128 pseudonymized specimens with known qRT-PCR Ct values (16 to 34) from the frozen
129 nasopharyngeal swab specimen library of Finnish Institute of Health and Welfare, Helsinki,
130 Finland, in undefined transport mediums, were tested. The qRT-PCR protocol was an in-house
131 method based on the primers and probes by Corman et al. (2020) (3). The cohort consisted
132 mostly of symptomatic, but in part also of asymptomatic subjects, while the detailed information

133 for each subject was not available for this study. The specimens were in either reddish (N=22) or
134 colorless (N=23) solutions. The samples were diluted into the mariPOC RTI sample buffer in
135 one-to-one (1:1) ratio and analyzed with the mariPOC test. The positivity rate of the mariPOC
136 test was compared to different qRT-PCR Ct value categories.

137 **Clinical validation.** Nasopharyngeal swab specimens (N=211) were collected from patients
138 visiting primary healthcare COVID-19 drive-in stations of Mehiläinen Oy in Helsinki capital
139 area of Finland from March to April 2020. The enrollment criteria were respiratory infection
140 symptoms and clinician's suspicion of COVID-19, the official criteria for COVID-19-testing in
141 Finland and at the clinical study sites at the time of the study. The samples were taken with a
142 flocked swab from the nasopharynx (8 to 12 cm deep for adults and 4 to 8 cm deep for children)
143 by rotating the swab in nasopharyngeal cavity for 10 seconds.

144 Two consecutive specimens were collected from 127 patients giving an oral consent to
145 participate in the study. The specimens were collected during an internal laboratory method
146 validation study, which does not require external ethical review board permission and was not
147 linked with recruitment or treatment of patients (36). The study was approved by the responsible
148 chief physician of Mehiläinen Oy. The specimen for standard of care testing was collected first.
149 These specimens were analyzed after RNA extraction with AllplexTM 2019-nCoV RT-PCR assay
150 (Seegene Inc., Republic of Korea) at Seoul Clinical laboratories (Republic of Korea). AllplexTM
151 2019-nCoV RT-PCR assay detects E, N and RdRP genes (37). The second swab specimen was
152 kept in a dry tube at +4 °C for a maximum of 8 hours and stored frozen until analysis with the
153 mariPOC SARS-CoV-2 test.

154 For 84 patients, one specimen was collected. These swabs were suspended into saline (0.5–1
155 mL) and analyzed with Amplidiag COVID-19 qRT-PCR assay including RNA extraction
156 (Mobidiag Ltd, Finland) at Vita Laboratorio Ltd (Finland). Amplidiag COVID-19 qRT-PCR
157 assay detects N and ORF1ab genes (38). The leftover saline specimens were stored frozen until
158 analysis with the mariPOC SARS-CoV-2 test.

159 The dry swab specimens and leftover saline samples were analyzed retrospectively with the
160 mariPOC test by two operators following the manufacturer's instructions. Briefly, dry swabs
161 were suspended into 1.3 mL of the mariPOC RTI sample buffer and the leftover saline samples
162 (range 0.1–0.65 mL) were diluted with RTI sample buffer to a final volume of 1.3 mL.

163 When a discrepant result between the mariPOC and comparator RT-PCR was obtained, the swab
164 samples taken for the mariPOC were confirmatory tested at the Department of Clinical
165 Microbiology, Turku University Hospital (Finland) with an in-house reference qRT-PCR
166 detecting E, N and RdRP genes (3).

167 **RESULTS**

168 **Analytical sensitivity.** LoD of the mariPOC SARS-CoV-2 test was 22 PFU/test in 20 μ L
169 reaction volume when all twenty replicates gave a positive test result. In 50% tissue culture
170 infective dose units, this corresponds to 40 TCID₅₀/test (39). The calculated LoD in qPCR Ct
171 units was 28.

172 **Cross-reactivity.** The mariPOC test had no cross-reactions. The mariPOC test did not cross-
173 react with seasonal coronaviruses OC43, 229E, or NL63, but it detected the recombinant N-
174 protein of SARS-CoV-1. Detailed information is shown in supplemental material.

175 **Verification study.** Overall, 21 out of 45 verification samples were positive with the mariPOC
176 (Figure 2). The test showed 90% positivity rate compared to qRT-PCR for Ct values 25 and
177 lower (Table 1). Above the Ct value 25, the positivity rate of the mariPOC declined as typical for
178 an antigen test.

179 **Clinical validation.** Prevalence of SARS-CoV-2 in the study cohort was 6%, which is well in
180 alignment with the prevalence during the study time in the geographical area (5%). Considering
181 the confirmatory qRT-PCR results, the mariPOC SARS-CoV-2 test and the primary comparator
182 RT-PCR detected 12 and 13 true positive samples, respectively. In comparison to the PCR
183 testing, sensitivity and specificity of the mariPOC test were 92.3% (12/13) and 100.0%
184 (198/198), respectively (Table 2). In the preliminary result reporting phase at 20 minutes, the
185 mariPOC test detected 75.0% (9/12) of the positive samples, compared to the final reporting
186 phase in 2 hours, and the specificity was 100.0% (198/198). Analytical specificity of the qRT-
187 PCR was 99.5% (197/198). Detailed description of positive samples is shown in supplemental
188 material.

189 **DISCUSSION**

190 When setting up a diagnostic process or choosing a diagnostic method, one should carefully
191 consider, to start with, whether the disease, clinical condition and use case, require high
192 sensitivity for ruling out or high specificity for ruling in. There is a need for both in fighting the
193 COVID-19 pandemic. In general, analytically highly sensitive testing, such as PCR testing, is
194 good at ruling out a disease (e.g. keeping a ward clean) while highly specific testing, such as
195 antigen testing, is good at ruling in a disease (e.g. acute infection diagnostics and assessing
196 infectiousness). Because of rapidity and lesser logistic challenges compared to central lab testing,

197 antigen testing is particularly good in surveillance, field-testing, screening of masses, cohorting
198 of inpatients, acute disease diagnostics, and in assessing the infectiousness of individuals (13,
199 40). Especially when disease prevalence is low, clinical specificity of the screening and
200 diagnostic testing should be emphasized to keep unnecessary quarantines and economic damages
201 at minimum while still allowing sufficient enough infection control (29).

202 According to scientific data, to effectively prevent spread of the disease, pandemic control
203 should prioritize accessibility, frequency of testing, and rapid sample-to-answer time over test
204 sensitivity (38, 41, 42). Viral load and probability to infect others is highest just prior to onset of
205 symptoms and during the symptomatic phase (43).

206 We describe here analytical and clinical verification and validation of mariPOC SARS-CoV-2
207 test sensitivity and specificity. Determination of LoD was performed with UV-inactivated viral
208 culture supernatant and showed that only 22 PFU (40 TCID₅₀) per test was needed for positive
209 test result with $\geq 95\%$ confidence. Based on high identity (89.1%) between SARS-CoV-1
210 (Uniprot entry, P59595) and SARS-CoV-2 (UniProt entry, P0DTC9) nucleocapsid protein
211 sequences, and obtaining positive result for purified SARS-CoV-1 nucleocapsid protein in cross-
212 reactivity testing (Table S1 in the supplemental material), it is highly likely that the mariPOC test
213 detects also the SARS-CoV-1 virus itself. Cross-reactions were not observed. A minor limitation
214 of the study is that cross-reactivity for MERS coronavirus and coronavirus HKU1 were assessed
215 using purified protein and sequence analysis (supplemental material) and not with clinical
216 samples or cultured virus.

217 Our verification cohort showed 90% positivity rate for the mariPOC below qRT-PCR Ct 25
218 (Table 1 and Figure 2). This was an excellent result taking into account that the samples were

219 unfavorable for the fluorescent mariPOC platform. Colorful transport media are not
220 recommended for mariPOC testing since they elevate fluorescent signal levels (44) and
221 unnecessarily dilute the samples, which reduces sensitivity. The obtained results were,
222 nevertheless, similar compared to what has been reported in the literature for the correlation
223 between SARS-CoV-2 viral culture and qRT-PCR results, as summarized in Table 1. In addition,
224 our results are in line with at least two other N-protein detecting tests that were evaluated against
225 RT-PCR and culture (35, 45). Several studies have shown that infectivity of SARS-CoV-2
226 declines rapidly in samples showing qRT-PCR Ct above 25, and viable virus is rarely isolated
227 after 8 days from onset of the symptoms. The detection of sole viral RNA, especially at low
228 levels without the detectable level of viral N-protein or culture positivity, is a questionable
229 marker of acute infection and infectiousness (10-14, 16, 46-48).

230 In the clinical validation study, the specificity of the mariPOC SARS-CoV-2 test was high
231 (100.0%), with high confidence (95% CI, 98.15% to 100.00%, exact Clopper-Pearson method),
232 in analysis of clinical nasopharyngeal swab specimens as native (preferred specimen type) or in
233 saline. The results suggest that the clinical sensitivity of the mariPOC test (92.3%) is similar to
234 rapid RT-PCR (93.4%), (38) when symptomatic patients suspected with acute COVID-19
235 infection are tested within the first five days of symptoms and reasonable (here 5%) prevalence
236 among tested samples. Recommended sample in the mariPOC test is native nasopharyngeal swab
237 specimen suspended into 1.3 mL of the RTI sample buffer. Other specimen types may yield in
238 lower apparent sensitivity. In the clinical validation, suspending part of the swabs first into saline
239 prior to the addition of RTI sample buffer diluted the specimens 2 to 10 times (1 to 3 in Ct
240 values) more than the recommended sample pretreatment. Additional dilution lowers the

241 sensitivity compared to the recommended protocol, and could have lead to an underestimation of
242 the test sensitivity.

243 Strengths of the validation study included that the specimens were collected in the early phase of
244 the COVID-19 pandemic in Finland that minimized the detection of RNA persistence with the
245 RT-PCR among the cohort population. In addition, this study was conducted by using the
246 mariPOC test as instructed by the test manufacturer, while according to a recent review, three-
247 quarters of studies evaluating SARS-CoV-2 tests did not follow the instructions given by test
248 manufacturers (49).

249 Limitations of the validation study were that the patient characteristics and the number of
250 symptomatic days before sampling were not available for the study. Another limitation was the
251 use of two different PCRs, and low number of positive cases, which gives relatively wide
252 confidence range for the sensitivity (95% CI, 64.0% to 99.8%). Freezing and thawing of the
253 samples prior to mariPOC testing was also a limitation. However, if any, this could have had a
254 negative effect on the mariPOC test sensitivity and, hence, the study at least did not overestimate
255 the sensitivity of the mariPOC SARS-CoV-2 test.

256 **Conclusions.** In conclusion, the mariPOC SARS-CoV-2 test is an automated, highly specific and
257 clinically accurate test with rapid sample-to-answer time for individuals with clinical suspicion
258 and in acute phase of an infection. The closed tube test system and the design of operational
259 steps minimize specimen handling and possible exposure of user to infectious material. The
260 multianalyte syndromic tests help to differentiate between SARS-CoV-2 and other viruses, such
261 as influenza. The single analyte test provides high capacity of 300 samples a day at the point-of-
262 care. Objective result read-out and LIS connectability minimize manual work and human errors.

263 Our study together with other scientific data suggests that the mariPOC can detect most
264 infectious individuals already in 20 minutes while similar clinical sensitivity than that of rapid
265 PCR is achieved in 2 hours or less. The positivity rate of mariPOC compared to qRT-PCR Ct
266 values in clinical samples is very high up to Ct 25, and samples up to Ct 29 can be detected
267 (Figure 2, Supplementary table 2). This data is in good agreement with the LoD 28 in qPCR Ct
268 values with the inactivated virus. The detection of conserved epitope in the N-protein of SARS
269 coronaviruses with the mariPOC likely provides accurate information about infectiousness
270 similarly to other antigen tests and viral culture and suggests ability to detect also emerging virus
271 variants. Further studies using viral culture as comparative method and follow-up of
272 infectiousness of patients using antigen detection are needed in order to optimize viral
273 respiratory tract infection management.

274 **SUPPLEMENTAL MATERIAL**

275 Supplemental material is available online only.

276 SUPPLEMENTAL FILE 1, PDF file, 0.4 MB.

277 **FUNDING** ArcDia International Ltd contributed the study with the mariPOC test system and
278 consumables. The study was partly supported by Business Finland, the Finnish Funding Agency
279 for Innovation, under the project reference 35239/31/2020.

280 **CONFLICTS OF INTEREST**

281 JMK, PA and JOK are employees at ArcDia International Ltd.

282 **ACKNOWLEDGEMENTS**

283 We thank Vita laboratories Ltd and Seoul Clinical Laboratory for performing RT-PCR analyses.

284 **AUTHOR CONTRIBUTIONS**

285 JMK and PA: Major contributions in the development of the mariPOC test, in scientific design
286 and execution of the studies, result analysis, scientific analysis, and writing of the manuscript.

287 KH: Major contributions in providing specimens for clinical validation, in scientific analysis and
288 revising the manuscript.

289 AH: Major contributions in providing specimens for verification, in scientific analysis and
290 revising the manuscript.

291 NI and CS-K: Major contributions in scientific analysis, and revision of the manuscript.

292 JOK: Major contributions in the development of the mariPOC test and in scientific design,
293 execution, and analysis of the results, and revision of the manuscript.

294 **REFERENCES**

295 1. Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W, Si H, Zhu Y, Li B, Huang C, Chen H, Chen J,
296 Luo Y, Guo H, Jiang R, Liu M, Chen Y, Shen X, Wang X, Zheng X, Zhao K, Chen Q, Deng F, Liu L,
297 Yan B, Zhan F, Wang Y, Xiao G, Shi Z. 2020. A pneumonia outbreak associated with a new coronavirus
298 of probable bat origin. *Nature* 579:270-273. <https://doi.org/10.1038/s41586-020-2012-7>.

299 2. Boni MF, Lemey P, Jiang X, Lam TT, Perry BW, Castoe TA, Rambaut A, Robertson DL. 2020.
300 Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic.
301 *Nat Microbiol* 5:1408-1417. <https://doi.org/10.1038/s41564-020-0771-4>.

- 302 3. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, Bleicker T, Brünink S, Schneider
303 J, Schmidt ML, Mulders DG, Haagmans BL, van der Veer B, van den Brink S, Wijsman L, Goderski G,
304 Romette J, Ellis J, Zambon M, Peiris M, Goossens H, Reusken C, Koopmans MP, Drosten C. 2020.
305 Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill
306 25:<https://dx.doi.org/10.2807%2F1560-7917.ES.2020.25.3.2000045>.
- 307 4. Gaunt ER, Hardie A, Claas ECJ, Simmonds P, Templeton KE. 2010. Epidemiology and clinical
308 presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years
309 using a novel multiplex real-time PCR method. J Clin Microbiol 48:2940-2947.
310 <https://doi.org/10.1128/jcm.00636-10>.
- 311 5. Prill MM, Iwane MK, Edwards KM, Williams JV, Weinberg GA, Staat MA, Willby MJ, Talbot HK,
312 Hall CB, Szilagyi PG, Griffin MR, Curns AT, Erdman DD. 2012. Human coronavirus in young children
313 hospitalized for acute respiratory illness and asymptomatic controls. Pediatr Infect Dis J 31:235-240.
314 <https://doi.org/10.1097/inf.0b013e31823e07fe>.
- 315 6. Rhedin S, Lindstrand A, Rotzén-Östlund M, Tolfvenstam T, Ohrmalm L, Rinder MR, Zwegberg-
316 Wirgart B, Ortqvist A, Henriques-Normark B, Broliden K, Naucler P. 2014. Clinical utility of PCR for
317 common viruses in acute respiratory illness. Pediatrics 133:538. <https://doi.org/10.1542/peds.2013-3042>.
- 318 7. Rhedin S, Lindstrand A, Hjelmgren A, Ryd-Rinder M, Öhrmalm L, Tolfvenstam T, Örtqvist Å,
319 Rotzén-Östlund M, Zwegberg-Wirgart B, Henriques-Normark B, Broliden K, Naucler P. 2015.
320 Respiratory viruses associated with community-acquired pneumonia in children: matched case-control
321 study. Thorax 70:847-853. <https://doi.org/10.1136/thoraxjnl-2015-206933>.
- 322 8. Chau NVV, Thanh Lam V, Thanh Dung N, Yen LM, Minh NNQ, Hung LM, Ngoc NM, Dung NT,
323 Man DNH, Nguyet LA, Nhat LTH, Nhu LNT, Ny NTH, Hong NTT, Kestelyn E, Dung NTP, Xuan TC,
324 Hien TT, Thanh Phong N, Tu TNH, Geskus RB, Thanh TT, Thanh Truong N, Binh NT, Thuong TC,

- 325 Thwaites G, Tan LV. 2020. The natural history and transmission potential of asymptomatic SARS-CoV-2
326 infection. *Clin Infect Dis* 71:2679-2687. <https://doi.org/10.1093/cid/ciaa711>.
- 327 9. Kissler SM, Fauver JR, Mack C, Tai C, Shiue KY, Kalinich CC, Jednak S, Ott IM, Vogels CBF,
328 Wohlgemuth J, Weisberger J, DiFiori J, J. Anderson D, Mancell J, Ho DD, Grubaugh ND, Grad YH.
329 2020. Viral dynamics of SARS-CoV-2 infection and the predictive value of repeat testing. medRxiv
330 <https://doi.org/10.1101/2020.10.21.20217042>.
- 331 10. Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, Taylor J, Spicer K, Bardossy
332 AC, Oakley LP, Tanwar S, Dyal JW, Harney J, Chisty Z, Bell JM, Methner M, Paul P, Carlson CM,
333 McLaughlin HP, Thornburg N, Tong S, Tamin A, Tao Y, Uehara A, Harcourt J, Clark S, Brostrom-Smith
334 C, Page LC, Kay M, Lewis J, Montgomery P, Stone ND, Clark TA, Honein MA, Duchin JS, Jernigan JA.
335 2020. Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility. *N Engl J*
336 *Med* 382:2081-2090. <https://doi.org/10.1056/nejmoa2008457>.
- 337 11. Bullard J, Dust K, Funk D, Strong JE, Alexander D, Garnett L, Boodman C, Bello A, Hedley A,
338 Schiffman Z, Doan K, Bastien N, Li Y, Van Caesele PG, Poliquin G. 2020. Predicting infectious SARS-
339 CoV-2 from diagnostic samples. *Clin Infect Dis* 71:2663–2666. <https://doi.org/10.1093/cid/ciaa638>.
- 340 12. La Scola B, Le Bideau M, Andreani J, Hoang VT, Grimaldier C, Colson P, Gautret P, Raoult D. 2020.
341 Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2
342 patients from infectious disease wards. *Eur J Clin Microbiol Infect Dis* 39:1059-1061.
343 <https://doi.org/10.1007/s10096-020-03913-9>.
- 344 13. Pekosz A, Cooper CK, Parvu V, Li M, Andrews JC, Manabe YC, Kodsi S, Leitch J, Gary DS, Roger-
345 Dalbert C. 2020. Antigen-based testing but not real-time PCR correlates with SARS-CoV-2 virus culture.
346 *Clin Infect Dis* ciaa1706. <https://doi.org/10.1093/cid/ciaa1706>.

- 347 14. Singanayagam A, Patel M, Charlett A, Lopez Bernal J, Saliba V, Ellis J, Ladhani S, Zambon M,
348 Gopal R. 2020. Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases
349 of COVID-19, England, January to May 2020. *Euro Surveill* 25:[https://doi.org/10.2807/1560-](https://doi.org/10.2807/1560-7917.es.2020.25.32.2001483)
350 [7917.es.2020.25.32.2001483](https://doi.org/10.2807/1560-7917.es.2020.25.32.2001483).
- 351 15. Cao S, Gan Y, Wang C, Bachmann M, Wei S, Gong J, Huang Y, Wang T, Li L, Lu K, Jiang H, Gong
352 Y, Xu H, Shen X, Tian Q, Lv C, Song F, Yin X, Lu Z. 2020. Post-lockdown SARS-CoV-2 nucleic acid
353 screening in nearly ten million residents of Wuhan, China. *Nature Communications* 11:1-7.
354 <https://doi.org/10.1038/s41467-020-19802-w>.
- 355 16. Jaafar R, Aherfi S, Wurtz N, Grimaldier C, Van Hoang T, Colson P, Raoult D, La Scola B. 2020.
356 Correlation Between 3790 Quantitative Polymerase Chain Reaction–Positives Samples and Positive Cell
357 Cultures, Including 1941 Severe Acute Respiratory Syndrome Coronavirus 2 Isolates. *Clinical Infectious*
358 *Diseases* <https://doi.org/10.1093/cid/ciaa1491>.
- 359 17. Inagaki K, Song M, Crumpton J, DeBeauchamp J, Jeevan T, Tuomanen EI, Webby RJ, Hakim H.
360 2016. Correlation Between the Interval of Influenza Virus Infectivity and Results of Diagnostic Assays in
361 a Ferret Model. *J Infect Dis* 213:407-410. <https://doi.org/10.1093/infdis/jiv331>.
- 362 18. Pollock AM, Lancaster J. 2020. Asymptomatic transmission of covid-19. *BMJ*
363 371:m4851:<http://dx.doi.org/10.1136/bmj.m4851>.
- 364 19. Wada M, Lokugamage KG, Nakagawa K, Narayanan K, Makino S. 2018. Interplay between
365 coronavirus, a cytoplasmic RNA virus, and nonsense-mediated mRNA decay pathway. *Proc Natl Acad*
366 *Sci U S A* 115:E10157-E10166. <https://doi.org/10.1073/pnas.1811675115>.
- 367 20. Almazán F, Galán C, Enjuanes L. 2004. The nucleoprotein is required for efficient coronavirus
368 genome replication. *J Virol* 78:12683-12688. <https://doi.org/10.1128/jvi.78.22.12683-12688.2004>.

- 369 21. Zúñiga S, Cruz JLG, Sola I, Mateos-Gómez PA, Palacio L, Enjuanes L. 2010. Coronavirus
370 nucleocapsid protein facilitates template switching and is required for efficient transcription. *J Virol*
371 84:2169-2175. <https://doi.org/10.1128/jvi.02011-09>.
- 372 22. Alexandersen S, Chamings A, Bhatta TR. 2020. SARS-CoV-2 genomic and subgenomic RNAs in
373 diagnostic samples are not an indicator of active replication. *Nat Commun* 11:6059.
374 <https://doi.org/10.1038/s41467-020-19883-7>.
- 375 23. Hofmann MA, Sethna PB, Brian DA. 1990. Bovine coronavirus mRNA replication continues
376 throughout persistent infection in cell culture. *J Virol* 64:4108-4114.
377 <https://doi.org/10.1128/jvi.64.9.4108-4114.1990>.
- 378 24. Wernike K, Keller M, Conraths FJ, Mettenleiter TC, Groschup MH, Beer M. 2020. Pitfalls in SARS-
379 CoV-2 PCR diagnostics. *Transbound Emerg Dis* <https://doi.org/10.1111/tbed.13684>.
- 380 25. Santarpia JL, Rivera DN, Herrera VL, Morwitzer MJ, Creager HM, Santarpia GW, Crown KK, Brett-
381 Major DM, Schnaubelt ER, Broadhurst MJ, Lawler JV, Reid SP, Lowe JJ. 2020. Aerosol and surface
382 contamination of SARS-CoV-2 observed in quarantine and isolation care. *Sci Rep* 10:12732.
383 <https://doi.org/10.1038/s41598-020-69286-3>.
- 384 26. Zhou J, Otter JA, Price JR, Cimpeanu C, Garcia DM, Kinross J, Boshier PR, Mason S, Bolt F,
385 Holmes AH, Barclay WS. 2020. Investigating SARS-CoV-2 surface and air contamination in an acute
386 healthcare setting during the peak of the COVID-19 pandemic in London. *Clin Infect Dis*
387 <https://doi.org/10.1093/cid/ciaa905>.
- 388 27. Curran T, McCaughey C, Ellis J, Mitchell SJ, Feeney SA, Watt AP, Mitchell F, Fairley D, Crawford
389 L, McKenna J, Coyle PV. 2012. False-positive PCR results linked to administration of seasonal influenza
390 vaccine. *J Med Microbiol* 61:332-338. <https://doi.org/10.1099/jmm.0.036178-0>.

- 391 28. Surkova E, Nikolayevskyy V, Drobniowski F. 2020. False-positive COVID-19 results: hidden
392 problems and costs. *The lancet respiratory medicine* 8:1167-1168. [http://dx.doi.org/10.1016/S2213-](http://dx.doi.org/10.1016/S2213-2600(20)30453-7)
393 [2600\(20\)30453-7](http://dx.doi.org/10.1016/S2213-2600(20)30453-7).
- 394 29. Mina MJ, Andersen KG. 2020. COVID-19 testing: One size does not fit all. *Science* 371:126-127.
395 <https://doi.org/10.1126/science.abe9187>.
- 396 30. Bruning AHL, Aatola H, Toivola H, Ikonen N, Savolainen-Kopra C, Blomqvist S, Pajkrt D, Wolthers
397 KC, Koskinen JO. 2018. Rapid detection and monitoring of human coronavirus infections. *New Microbes*
398 *New Infect* 24:52-55. <https://doi.org/10.1016/j.nmni.2018.04.007>.
- 399 31. Vandroux D, Allou N, Jabot J, Li Pat Yuen G, Brottet E, Roquebert B, Martinet O. 2018. Intensive
400 care admission for Coronavirus OC43 respiratory tract infections. *Med Mal Infect* 48:141-144.
401 <https://doi.org/10.1016/j.medmal.2018.01.001>.
- 402 32. Hänninen P, Soini A, Meltola N, Soini J, Soukka J, Soini E. 2000. A new microvolume technique for
403 bioaffinity assays using two-photon excitation. *Nat Biotechnol* 18:548-550.
404 <https://doi.org/10.1038/75421>.
- 405 33. Koskinen JO, Vainionpää R, Meltola NJ, Soukka J, Hänninen PE, Soini AE. 2007. Rapid method for
406 detection of influenza a and B virus antigens by use of a two-photon excitation assay technique and dry-
407 chemistry reagents. *J Clin Microbiol* 45:3581-3588. <https://doi.org/10.1128/JCM.00128-07>.
- 408 34. Gunell M, Antikainen P, Porjo N, Irjala K, Vakkila J, Hotakainen K, Kaukoranta SS, Hirvonen JJ,
409 Saha K, Manninen R, Forsblom B, Rantakokko-Jalava K, Peltola V, Koskinen JO, Huovinen P. 2016.
410 Comprehensive real-time epidemiological data from respiratory infections in Finland between 2010 and
411 2014 obtained from an automated and multianalyte mariPOC® respiratory pathogen test. *Eur J Clin*
412 *Microbiol Infect Dis* 35:405-413. <https://doi.org/10.1007/s10096-015-2553-0>.

- 413 35. Rusanen J, Kareinen L, Szivovicza L, Uğurlu H, Levanov L, Jääskeläinen A, Ahava M, Kurkela S,
414 Saksela K, Hedman K, Vapalahti O, Hepojoki J. 2020. A generic, scalable, and rapid TR-FRET –based
415 assay for SARS-CoV-2 antigen detection. medRxiv <https://doi.org/10.1101/2020.12.07.20245167>.
- 416 36. Vakkila J, Koskinen JO, Brandt A, Muotiala A, Liukko V, Soittu S, Meriluoto S, Vesalainen M,
417 Huovinen P, Irjala K. 2015. Detection of Group A Streptococcus from Pharyngeal Swab Samples by
418 Bacterial Culture Is Challenged by a Novel mariPOC Point-of-Care Test. *Journal of Clinical*
419 *Microbiology* 53:2079-2083. <https://doi.org/10.1128/jcm.00018-15>.
- 420 37. Liotti FM, Menchinelli G, Marchetti S, Morandotti GA, Sanguinetti M, Posteraro B, Cattani P. 2020.
421 Evaluation of three commercial assays for SARS-CoV-2 molecular detection in upper respiratory tract
422 samples. *European Journal of Clinical Microbiology & Infectious Diseases: Official Publication of the*
423 *European Society of Clinical Microbiology* 40:269-277. <https://doi.org/10.1007/s10096-020-04025-0>.
- 424 38. Jokela P, Jääskeläinen AE, Jarva H, Holma T, Ahava MJ, Mannonen L, Lappalainen M, Kurkela S,
425 Loginov R. 2020. SARS-CoV-2 sample-to-answer nucleic acid testing in a tertiary care emergency
426 department: evaluation and utility. *J Clin Virol* 131:104614. <https://doi.org/10.1016/j.jcv.2020.104614>.
- 427 39. Wulff NH, Tzatzaris M, Young PJ. 2012. Monte Carlo simulation of the Spearman-Kaerber TCID50.
428 *J Clin Bioinforma* 2:5. <https://doi.org/10.1186/2043-9113-2-5>.
- 429 40. Guglielmi G. 2020. Fast coronavirus tests: what they can and can't do. *Nature* 585:496-498.
430 <https://doi.org/10.1038/d41586-020-02661-2>.
- 431 41. Larremore DB, Wilder B, Lester E, Shehata S, Burke JM, Hay JA, Tambe M, Mina MJ, Parker R.
432 2020. Test sensitivity is secondary to frequency and turnaround time for COVID-19 screening. *Sci Adv*
433 7:eabd5393. <https://doi.org/10.1126/sciadv.abd5393>.

- 434 42. Mina MJ, Parker R, Larremore DB. 2020. Rethinking Covid-19 Test Sensitivity - A Strategy for
435 Containment. *N Engl J Med* 383:e120. <https://doi.org/10.1056/nejmp2025631>.
- 436 43. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, Lau YC, Wong JY, Guan Y, Tan X, Mo X, Chen Y,
437 Liao B, Chen W, Hu F, Zhang Q, Zhong M, Wu Y, Zhao L, Zhang F, Cowling BJ, Li F, Leung GM.
438 2020. Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nat Med* 26:672-675.
439 <https://doi.org/10.1038/s41591-020-0869-5>.
- 440 44. Koskinen JM, Soukka JM, Meltola NJ, Koskinen JO. 2018. Microbial identification from feces and
441 urine in one step by two-photon excitation assay technique. *Journal of Immunological Methods* 460:113-
442 118. <https://doi.org/10.1016/j.jim.2018.06.017>.
- 443 45. Albert E, Torres I, Bueno F, Huntley D, Molla E, Fernández-Fuentes MÁ, Martínez M, Poujois S,
444 Forqué L, Valdivia A, Solano de la Asunción, Carlos, Ferrer J, Colomina J, Navarro D. 2020. Field
445 evaluation of a rapid antigen test (Panbio™ COVID-19 Ag Rapid Test Device) for COVID-19 diagnosis
446 in primary healthcare centres. *Clin Microbiol Infect* <https://doi.org/10.1016/j.cmi.2020.11.004>.
- 447 46. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, Niemeyer D, Jones TC,
448 Vollmar P, Rothe C, Hoelscher M, Bleicker T, Brünink S, Schneider J, Ehmann R, Zwirgmaier K,
449 Drosten C, Wendtner C. 2020. Virological assessment of hospitalized patients with COVID-2019. *Nature*
450 581:465-469. <https://doi.org/10.1038/s41586-020-2196-x>.
- 451 47. Sohn Y, Jeong SJ, Chung WS, Hyun JH, Baek YJ, Cho Y, Kim JH, Ahn JY, Choi JY, Yeom J. 2020.
452 Assessing Viral Shedding and Infectivity of Asymptomatic or Mildly Symptomatic Patients with COVID-
453 19 in a Later Phase. *J Clin Med* 9:2924. <https://doi.org/10.3390/jcm9092924>.
- 454 48. Basile K, McPhie K, Carter I, Alderson S, Rahman H, Donovan L, Kumar S, Tran T, Ko D, Sivaruban
455 T, Ngo C, Toi C, O'Sullivan MV, Sintchenko V, Chen SC-, Maddocks S, Dwyer DE, Kok J. 2020. Cell-

456 based culture of SARS-CoV-2 informs infectivity and safe de-isolation assessments during COVID-19.

457 Clin Infect Dis ciaa1579. <https://doi.org/10.1093/cid/ciaa1579>.

458 49. Dinnes J, Deeks JJ, Adriano A, Berhane S, Davenport C, Dittrich S, Emperador D, Takwoingi Y,

459 Cunningham J, Beese S, Dretzke J, Ferrante di Ruffano L, Harris IM, Price MJ, Taylor-Phillips S, Hooft

460 L, Leeflang MM, Spijker R, Van den Bruel A. 2020. Rapid, point-of-care antigen and molecular-based

461 tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev 8:CD013705.

462 <https://doi.org/10.1002/14651858.cd013705>.

463 **Table 1** Cumulative positivity rates of viral culture (three studies) and mariPOC (verification study data)

464 compared to qRT-PCR.(10, 12, 14)

	Arons	La Scola	Singanayagam	mariPOC
Ct < 25	87%	83%	85%	90% (18/20)
Ct < 27	84%	79%	NA	71% (20/28)
Ct < 30	67%	75%	74%	57% (21/37)
Ct < 32	66%	70%	49%*	53% (21/40)
Overall	63%	68%	30%	47% (21/45)

465 *Ct < 35, NA = not applicable

466


467 **Table 2**

468 Performance of mariPOC SARS-CoV-2 test (validation study data) when compared with the qRT-PCR

469 methods.

mariPOC	No. of specimens				Sensitivity (95% CI)	Specificity	PPV (95% CI)	NPV (95% CI)	Accuracy (95% CI)
	TP	FP	TN	FN					
Final	12	0	198	1	92.3 (64.0–99.8)	100.0	100.0	99.5 (96.8–99.9)	99.5 (97.4–100.0)
Preliminary	9	0	198	4	69.2 (38.6–90.9)	100.0	100.0	98.9 (95.6–99.1)	98.1 (95.2–99.5)

470 TP = true positive, FP = false positive, TN = true negative, PPV = positive predictive value, NPV = negative predictive value, CI = confidence
471 interval (exact Clopper-Pearson method).




- ① Add the specimen ② Add the buffer ③ Vortex

472
473

Figure 1


474 Sample pretreatment in the mariPOC SARS-CoV-2 test before placing the sample tube into the analyzer
475 for automated analysis and subsequent test result read out objectively as positive or negative.




476
477

Figure 2


478 Ct values of qRT-PCR for mariPOC test positive (green) and negative (red) samples in the verification
479 sample cohort. Dotted and dashed line at Ct 25 and 29, respectively.



1 Add the specimen



2 Add the buffer



3 Vortex

